AzTrials
AzTrials

EpilepsyNCT02988050

Conscious Sedation for Epilepsy Surgery

A study testing Remifentanil, Dexmedetomidine and Propofol in people with Epilepsy, run by Menoufia University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sixty patients were randomly allocated into two groups, group PD and group PR, thirty patients in each group. Patients in PD group received propofol and dexmedetomidine intravenous infusion and patients in PR group received propofol and remifentanil intravenous infusion. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Epilepsy
What is being tested?
Remifentanil, Dexmedetomidine and Propofol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
No sites listed yet
Study dates
Aug 2013to Apr 2016
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients require conscious sedation for epilepsy surgery

Who cannot join

  • Patients refusal, allergy to drugs used, and uncooperative patients.

About this study

Official title: Propofol-dexmedetomidine Versus Propofol-remifentanil Conscious Sedation for Awake Craniotomy During Epilepsy Surgery

Sixty patients were randomly allocated into two groups, group PD and group PR, thirty patients in each group. Patients in PD group received propofol and dexmedetomidine intravenous infusion and patients in PR group received propofol and remifentanil intravenous infusion. Sedation score and patients' satisfaction, surgeon satisfaction, heart rate, mean arterial blood pressure, oxygen saturation, and side effects such as respiratory depression, nausea, vomiting, airway obstruction, and oxygen desaturation were recorded.

Read the detailed description

After approval from the ethics committee of Menoufia University Hospitals and informed written consent, the present study was conducted on sixty patients of both sexes. Patients' age was between 18-50 years, American society of anesthesiologists (ASA) I and II and scheduled for awake craniotomy for treatment of epilepsy. Exclusion criteria included patients with history of allergy to any of the drugs used for the study, patients with alcohol or substance abuse, pregnant females, patients with mental instability, morbid obese patients, and patients with liver, kidney, or cardiac comorbidities.

Patients were randomly allocated using computerized software into two groups, thirty patients in each group to receive intra-operative either propofol-dexmedetomidine (PD group) or propofol-remifentanil (PR group) intravenous infusion. All patients received their routine treatment for epilepsy at their scheduled time before surgery. All patients were fully monitored intra-operatively for heart rate, non-invasive blood pressure, oxygen saturation, respiratory rate, and bi-spectral index (BIS). Oxygen was supplied to all patients via nasal cannula peri-operatively.

Anaesthesia was achieved by regional scalp block and IV sedation. Regional blockade of the scalp was performed using bupivacaine 0.5% and 2% lidocaine with epinephrine 1/200.000. The branches of the cranial nerves blocked were supratrochlear, supraorbital, auriculotemporal, greater and lesser occipital, great auricular, zygomatic, and infraorbital nerves. Supplemental local anesthetic solution was used to infiltrate along the incision lines prior to skin incision. During craniotomy, a mixture of 0.25% bupivacaine and lidocaine1% without epinephrine was used to anesthetize the dura mater. The maximum dose of lidocaine used did not exceed 4.5 mg kg -1 and for bupivacaine 3 mg kg -1.

All patients received propofol 1% with a starting intravenous infusion dose of 250 μg kg-1 min-1 for 15 min and then basal infusion dose at 50 μg kg-1min-1. Sedation was achieved for group PD by a combination of propofol and dexmedetomidine with a starting infusion dose of 1ug kg-1 hr -1 for 15 min, and then titrated down to 0.2μ g kg-1 hr-1.

In PR group, IV sedation was achieved by a combination of propofol and remifentanil at an initial bolus dose of 0.5 μg.kg-1 over 60 seconds and then a basal infusion of 0.1μg kg-1 min1. Insufficient sedation in both groups was treated with boluses of 250 μg kg-1 propofol. The total amount of propofol used in both groups was recorded.

Sedation was assessed using Ramsay sedation score.6 Patient scored (1) if was anxious, agitated, or restless. Patient scored (2) if was cooperative, oriented and tranquil. Score 3 was for patients responded to command only. Score (4) for patients exhibited brisk respond to light glabellar tap or loud auditory stimulus. Score (5) for patients exhibited a sluggish response to light glabellar tap or loud auditory stimulus. Score (6) was for patients exhibited no response. Score (1) means inadequate sedation, score (2 to 4) means acceptable sedation, and score (5) or (6) means excessive sedation. Bi-spectral index (BIS) was connected to all patients and recorded every half an hour intra-operatively until the end surgery.

For intraoperative neurophysiologic monitoring propofol infusion was stopped for 15 minutes to avoid interference.

Side effects such as respiratory depression (respiratory rate less than 8/min), nausea, vomiting, airway obstruction, oxygen desaturation (oxygen saturation less than 90 %), and hypotension or hypertension (20% decrease or increase from the base line) were recorded. In case of apnea, respiratory depression, oxygen desaturation, and airway obstruction or hypotension all infusions were stopped until normalization and then the infusion resumed at half the basal rate. Vomiting was treated with 4mg intravenous ondansetron and the total ondansetron consumption was recorded for both groups.

If intraoperative convulsions occurred at any time IV thiopental sodium was given at a dose 1-2 mg kg-1. General anaesthesia was given if indicated and the patient was removed from the study. The excluded patients were replaced according to the schedule of randomization to keep the number of the two groups. Indications for general anesthesia were failure of the regional block, marked patient irritability, severe airway obstruction required intubation, uncontrolled convulsions, and haemodynamic instability.

Patient's satisfaction was recorded using a score ranging from 0 not satisfied and 10 totally satisfied. Surgeon satisfaction regarding the operative conditions and the anesthetic technique was recorded as 0 very bad operative conditions, 1 moderate, and 2 good.

Statistical analysis Sample size calculation was calculated using graphed instant statistics version 3. Based on previous research, dexmedetomidine was expected to produce a decrease in the heart rate by about 10 beats /minute with a standard deviation of 10 and by choosing 5% level of significance and power of 90% the calculated sample size was 22 so that, the sample size used in the study was 30 patients to ensure reliable results.

Data were analyzed using SPSS 19 program. Student t-test was used for comparing data between the two groups. Chi square test was used to compare the incidence of side effects. P value of less than 0.05 was considered to be statistically significant.

Conditions
Epilepsy
Keywords
Epilepsy Surgery, Conscious sedation
Medical subject headings
Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RemifentanilDrug

    Remifentanil used for conscious sedation.

  • DexmedetomidineDrug

    Dexmedetomidine used for conscious sedation.

  • PropofolDrug

    Used for conscious sedation.

  • BupivacaineDrug

    Local anaesthetics

  • LidocaineDrug

    Local anaesthetic

  • EpinephrineDrug

    With local anaesthetic for skin infiltration.

Study groups in NCT02988050
Study groupRoleWhat they receive
Propofol-dexmedetomidineOtherPropofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
Receives: Drug: Dexmedetomidine; Drug: Propofol; Drug: Bupivacaine; Drug: Lidocaine; Drug: Epinephrine
Propofol-remifentanilOtherPropofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
Receives: Drug: Remifentanil; Drug: Propofol; Drug: Bupivacaine; Drug: Lidocaine; Drug: Epinephrine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patients Satisfaction

    Patient's satisfaction was recorded using a score ranging from 0 for not satisfied to 10 for totally satisfied.

    Measured: 1 hour after the operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2016 (estimated)
  2. Study startAug 2013
  3. Primary completionFeb 2016
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02988050
Sponsor's protocol ID
MenoufiaU2016
Status last verified
Sep 2020
First submitted
28 Nov 2016
Last updated
9 Oct 2020
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Remifentanil, Dexmedetomidine and Propofol in people with Epilepsy, run by Menoufia University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Oct 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patients Satisfaction (time frame: 1 hour after the operation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Conscious Sedation for Epilepsy Surgery (NCT02988050) | AzTrials